Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response contains multiple claims not supported by the supplied label excerpts (e.g., incidence rate, specific symptom descriptors, and regulatory-history/study numeric details). Only some general muscle-symptom reporting/discontinuation concepts are partially supported.
Category Scores
Accurate Statements
Muscle weakness can occur with Lipitor due to statin myopathy (and patients should report unexplained muscle pain/tenderness/weakness promptly).
Label 5.1 (myopathy defined as muscle aches or muscle weakness; report promptly unexplained muscle pain, tenderness, or weakness); Label 17.1 (report promptly unexplained muscle pain, tenderness, or weakness).
Lipitor therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.
Label 5.1 (discontinue if markedly elevated CPK levels occur or myopathy is diagnosed or suspected).
Unsupported Statements
Muscle cramps are reported in about 1 in 10,000 patients taking Lipitor.
No incidence rate for 'muscle cramps' is provided in the supplied label excerpts.
Muscle cramps caused by Lipitor can manifest as sudden, severe muscle pain.
The excerpts support reporting unexplained muscle pain/tenderness/weakness, but do not support the specific characterization 'sudden, severe' tied to 'muscle cramps.'
Muscle cramps caused by Lipitor can manifest as muscle spasms.
The supplied excerpts do not describe 'muscle spasms' as a manifestation.
Muscle cramps caused by Lipitor can manifest as tingling or numbness in the muscles.
The supplied excerpts do not support 'tingling or numbness in the muscles' specifically (peripheral neuropathy is listed in 6.2 but the claim is about muscle-specific tingling/numbness).
Patients should seek medical attention immediately for severe muscle pain that lasts for more than a few hours while taking Lipitor.
No duration threshold ('more than a few hours') is stated in the supplied label excerpts.
Patients should seek medical attention immediately for muscle cramps accompanied by fever, chills, or swelling while taking Lipitor.
The supplied excerpts do not state this specific set of systemic symptoms ('fever, chills, or swelling') in conjunction with muscle cramps.
Patients should seek medical attention immediately for muscle cramps severe enough to interfere with daily activities while taking Lipitor.
The supplied excerpts do not provide this severity standard.
Patients should seek medical attention immediately for muscle cramps accompanied by shortness of breath or chest pain while taking Lipitor.
The supplied excerpts do not link muscle symptoms to shortness of breath or chest pain.
A study reported that 12 patients taking Lipitor experienced severe muscle cramps.
The provided label content for 14 CLINICAL STUDIES is placeholder text and does not support this numeric claim.
One patient in the study required hospitalization for Lipitor-associated severe muscle cramps.
The provided label content for 14 CLINICAL STUDIES is placeholder text and does not support this hospitalization claim.
The FDA required Pfizer to add a warning to the Lipitor label in 2011 about the risk of muscle cramps.
No regulatory-history or 2011 labeling-change information is present in the supplied label excerpts.
If you experience muscle cramps while taking Lipitor, you should stop taking the medication and seek medical attention immediately.
The label language in the supplied excerpts supports discontinuation for diagnosed/suspected myopathy and prompt reporting of unexplained muscle pain/tenderness/weakness, but does not explicitly instruct to 'stop taking' for 'muscle cramps' specifically nor use the exact 'seek medical attention immediately' phrasing in the provided excerpts.
Contradictions
Important Omissions
The response does not accurately reflect that the label frames this as myopathy/rhabdomyolysis risk with guidance to report unexplained muscle pain/tenderness/weakness and to discontinue if myopathy is diagnosed/suspected or markedly elevated CPK occurs (without using the specific term 'muscle cramps' or additional detailed thresholds).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims add unsupported specificity (incidence rate, symptom manifestations, duration/trigger thresholds, cardiopulmonary/systemic symptom combinations) and a regulatory-history/study numeric narrative. While related concepts (report promptly, discontinue if myopathy suspected) are partially supported, over-specific instructions not anchored to the provided label could mislead patients.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple statements are not supported by the supplied prescribing information, including an incidence claim, specific symptom descriptors, study numeric details, and a 2011 FDA/Pfizer regulatory-history claim.
Suggested Improvement
Limit patient-facing statements to the label-supported guidance in 5.1 and 17.1 (risk of myopathy; report promptly unexplained muscle pain/tenderness/weakness; discontinue if markedly elevated CPK or myopathy diagnosed/suspected) and remove unsupported incidence, study numbers, regulatory-history, and non-labeled symptom/threshold combinations.